Overall survival in the NHL-B2 trial. Overall survival of all 689 eligible patients assigned to CHOP-21 (n = 178), CHOP-14 (n = 172), CHOEP-21 (n = 170), and CHOEP-14 (n = 169). Median time of observation for all patients was 58 months.